AI Article Synopsis
- Erythropoietin has the ability to activate and protect cells in the central nervous system (CNS) and heart (myocardium) from damage caused by reduced blood flow (ischemia) and low oxygen levels (hypoxia).
- The review highlights erythropoietin's potential therapeutic roles in treating conditions where these problems occur, such as stroke or heart attacks.
- Overall, it emphasizes the importance of erythropoietin in enhancing cell survival and function under stressful conditions related to reduced oxygen supply.
Article Abstract
The review describes the capability oferythropoietin to activate and protect the CNS cells and myocardium against ischemia and hypoxia.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Erythropoietin for the prevention of postoperative neurocognitive disorder in older adult patients undergoing total joint arthroplasty: a randomized controlled study.
BMC Anesthesiol
November 2024
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- Post-operative delirium (PD) is a common issue for older adults after surgery, affecting both health outcomes and healthcare costs.
- This study explored whether administering erythropoietin (EPO) before and after total joint arthroplasty could reduce the occurrence of PD in patients over 65 years old.
- Results indicated that while no patients in the EPO group developed PD compared to 3.2% in the placebo group, the difference wasn't statistically significant, and both groups exhibited similar cognitive function and inflammatory responses post-surgery.
Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment.
Pharmaceuticals (Basel)
April 2023
Department of Pharmaceutical Sciences, Biomanufacturing Research Institute & Technology Enterprise, North Carolina Central University, Durham, NC 27707, USA.
Neuroprotective drugs to protect the brain against cerebral ischemia and reperfusion (I/R) injury are urgently needed. Mammalian cell-produced recombinant human erythropoietin (rhuEPO) has been demonstrated to have excellent neuroprotective functions in preclinical studies, but its neuroprotective properties could not be consistently translated in clinical trials. The clinical failure of rhuEPO was thought to be mainly due to its erythropoietic activity-associated side effects.
View Article and Find Full Text PDFPotential anti-inflammatory effect of erythropoietin in non-clinical studies in vivo: A systematic review.
Biomed Pharmacother
July 2021
H&TRC-Health and Technology Research Center, ESTeSL-Lisbon School of Health Technology, Instituto Politécnico de Lisboa, 1990-096 Lisbon, Portugal; iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal. Electronic address:
Erythropoietin (EPO) is a hypoxia-induced hormone produced in adult kidneys with erythropoietic and non-erythropoietic effects. In vivo studies represent an important role to comprehend the efficacy and safety in the early phase of repurposing drugs. The aim is to evaluate the potential anti-inflammatory effect of EPO observed in animal models of disease.
View Article and Find Full Text PDFErythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone.
Front Immunol
September 2021
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease with variable clinical presentation, typically characterized by a relapsing-remitting course. SLE has a multifactorial pathogenesis including genetic, environmental, and hormonal factors that lead to loss of tolerance against self-antigens and autoantibody production. Mortality in SLE patients remains significantly higher than in the general population, in part because of the limited efficacy of available treatments and the associated toxicities.
View Article and Find Full Text PDFRenal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients.
Cell J
January 2014
1.Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Iran.
Currently many patients with chronic renal failure have profited from the use of erythropoietin to correct anemia (1,2). In chronic kidney disease, anemia is believed to be a surrogate index for tissue hypoxia that continues preexisting renal tissue injury (1-3). Erythropoietin is an essential glycoprotein that accelerates red blood cell maturation from erythroid progenitors and facilitates erythropoiesis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!